AN2 Therapeutics, Inc. (Nasdaq: ANTX) has announced a collaboration with the Drugs for Neglected Diseases initiative (DNDi) to advance the clinical development of AN2-502998, an oral drug candidate for the treatment of chronic Chagas disease. This partnership aims to leverage DNDi's extensive expertise in Chagas disease clinical trials, enhancing resource optimization and scientific execution. The initiative is part of DNDi's broader pipeline focused on novel treatments for Chagas disease. The collaboration will also include biomarker research and implementation studies to ensure effective diagnostics and treatments reach the patients in need. Results of the ongoing development have not yet been presented.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.